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Abstract
Background: Intensive multifactorial treatment aimed at prevention of cardiovascular (CV) disease may reduce left
ventricular (LV) echocardiographic abnormalities in diabetic subjects. Plasma N-terminal (NT)-proBNP predicts CV
mortality in diabetic patients but the association between P-NT-proBNP and the putative residual abnormalities in
such patients are not well described. This study examined echocardiographic measurements of LV hypertrophy,
atrial dilatation and LV dysfunction and their relation to P-NT-proBNP levels or subclinical coronary artery disease
(CAD) in type 2 diabetic patients with microalbuminuria receiving intensive multifactorial treatment.
Methods: Echocardiography including tissue Doppler imaging and P-NT-proBNP measurements were performed in
200 patients without prior CAD. Patients with P-NT-proBNP > 45.2 ng/L and/or coronary calcium score ≥ 400 were
stratified as high risk patients for CAD(n = 133) and examined for significant CAD by myocardial perfusion imaging
and/or CT-angiography and/or coronary angiography.
Results: LV mass index was 41.2 ± 10.9 g/m
2.7 and 48 (24%) patients had LV hypertrophy. LA and RA dilatation
were found in 54(27%) and 45(23%) patients, respectively, and LV diastolic dysfunction was found in 109(55%)
patients. Patients with increased P-NT-proBNP levels did not have more major echocardiographic abnormalities. In
70(53%) of 133 high risk patients significant CAD was demonstrated and patients with LV hypertrophy had
increased risk of significant CAD(adjusted odd ratio[CI] was 4.53[1.14-18.06]).
Conclusion: Among asymptomatic type 2 diabetic patients with microalbuminuria that received intensive
multifactorial treatment, P-NT-proBNP levels is not associated with echocardiographic abnormalities. LV diastolic
dysfunction was frequently observed, whereas LV hypertrophy was less frequent but associated with significant CAD.
Introduction
Current multifactorial treatment strategies for cardiovas-
cular (CV) disease aimed at reduction of established con-
ventional risk factors are effective [1], but not sufficient to
overcome the increased CV mortality in diabetic patients
[2]. We have previously identified elevated plasma
N-terminal-pro-brain natriuretic peptide (P-NT-proBNP)
as a strong predictor of CV mortality in type 2 diabetic
patients [3]. The causes of poor prognosis associated with
elevated P-NT-proBNP levels are not known in detail but
P-NT-proBNP levels correlate with echocardiography
measurements in diabetic populations not receiving multi-
factorial treatment [4]. Echocardiography in asymptomatic
high CV risk type 2 diabetic patients may disclose heart
abnormalities [5]. Selected echocardiographic abnormal-
ities, including left ventricular (LV) systolic and diastolic
dysfunction are related to CV risk factors and adverse CV
events [5,6]. For example, the prevalence of LV hypertro-
phy was high (43%) in asymptomatic type 2 diabetic
patients without CV disease and not taking antihyperten-
sive medications [7], and LV diastolic dysfunction was pre-
sent in almost 50% of asymptomatic subjects with newly
diagnosed type 2 diabetes [4].
Over the last decades, however, the intensive multifac-
torial treatment targeting hyperglycaemia, hypertension,
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tion may have reduced the previously reported high pre-
valence of LV hypertrophy and LV dysfunction in
diabetic subjects. Indeed, we have previously reported
that the prevalence of increased carotid intima-media
thickness (CIMT > 1.0 mm) was surprisingly low in a
cohort of 200 type 2 diabetic patients with microalbumi-
nuria that received intensive multifactorial treatment [8].
LV hypertrophy may regress and LV contractility
improve after treatment with drugs, e.g., renin angioten-
sin aldosterone system (RAAS)-blocking agents, that are
now part of recommended multifactorial treatment [9].
This improvement is associated with lower CV mortal-
ity, but the magnitude of LV hypertrophy regression and
CV risk reduction is less in diabetic patients compared
to nondiabetic controls [9]. In addition, a 2002 UK
study found that 44% of diabetic patients taking angio-
tensin-converting enzyme (ACE) inhibitors still had LV
hypertrophy, independent of blood pressures [5].
Furthermore, the previously reported high prevalence of
LV diastolic dysfunction in diabetic subjects has also
been suggested to be resistant to medical treatment [5].
The extent of residual echocardiographic abnormalities
and association with P-NT-proBNP levels has not been
reported in asymptomatic diabetic patients with microal-
buminuria that receive intensive multifactorial treat-
ment. Furthermore, the well-described association
between echocardiographic abnormalities, CV risk fac-
tors, and coronary artery disease (CAD) might be
diluted in patients receiving multifactorial treatment
with its attendant improved metabolic, lipid and blood
pressure control [10]. Accordingly, this study examined
echocardiographic abnormalities and their relation to P-
NT-proBNP levels or subclinical significant CAD in type
2 diabetic patients with microalbuminuria that received
intensive multifactorial treatment.
Methods
Patient cohort and investigations
In a cross-sectional study, we identified from January
2007 to February 2008, a consecutive cohort of 200 type
2 diabetic patients with microalbuminuria but without
prior CAD or other cardiac disease and normal plasma
creatinine (to allow for examinations with x-ray contrast
media). All patients received intensive multifactorial
intervention aimed at optimal glycaemic, lipid, and blood
pressure control, as well as antiplatelet therapy and life-
style modification according to the Steno-2 study [1].
The design, methods and cardiac examinations per-
formed in this cohort have previously been described
[10]. In brief, P-NT-proBNP was measured in all patients
and analyzed with an immunoassay. Cardiovascular
examinations in addition to echocardiography included
CIMT measured at the posterior wall 20 mm proximal to
the bifurcation bilaterally with a Siemens Acuson Cypress
MHz ultrasound scanner and with calculation of the
mean of measurements on both sides. We also calculated
the carotid compliance (l/mmHg) as previously described
[11]. Furthermore, systolic blood pressures in the ankle
and big toe were measured on both legs by strain gauge
technique and the lowers ankle and big toe pressures
were recorded and calculated as ankle-brachial and toe-
brachial blood pressure index [12]. Finally, the Agatston
coronary calcium score (CCS) was measured using a 16
multidetector-row CT scanner (Philips Precedence MX
8000 IDT 16 slice, Philips Medical Systems, Best, The
Netherlands) [13].
Risk stratification and assessment of CAD
Patients were stratified into high risk and low risk
groups based on elevated P-NT-proBNP and elevated
CCS as follows [10]: 1) P-NT-proBNP > 45.2 ng/l or
CCS ≥ 400 = high risk patients (n = 133); this P-NT-
proBNP cut-off value was selected as the median value
among the first 50 patients examined in the study and it
corresponded well with our earlier findings [3], and 2)
P-NT-proBNP ≤ 45.2 ng/l and CCS < 400 = low risk
patients (n = 67). High risk patients were examined
according to the following algorithm: 1) Patients with
P-NT-proBNP > 45.2 ng/l underwent myocardial perfu-
sion imaging (MPI);patients with abnormal MPI (n =
55) or CCS > 100 (n = 29) were referred for coronary
angiography (CAG), 2) Patients with P-NT-proBNP ≤
45.2 ng/l and CCS 400-1000 underwent CT angiography
(CTA) (n = 20); CTA was only used in patients with
CCS 400-1000 since heavy coronary artery calcifications
(CCS > 1000) compromise the validity of CTA [14] and
patients with abnormal CTA were referred for CAG
(n = 15), and 3) Patients with P-NT-proBNP ≤ 45.2 ng/l
and CCS > 1000 underwent MPI (n = 9); patients with
abnormal MPI (n = 6) were referred for CAG. Signifi-
cant CAD was defined as the presence of significant
(reversible and/or irreversible) myocardial perfusion
defects on MPI, and/or ≥ 70% stenosis of one or more
major ( ≥ 2 mm) epicardial coronary arteries at CAG.
The correlations between P-NT-proBNP, CTA, MPI and
CAG have been reported previously [10].
Echocardiography
Transthoracic echocardiography was performed using a
Philips IE 33 machine (Phillips Medical Systems, Best,
The Netherlands). All patients were examined with con-
ventional 2-D and Doppler modalities, combined with
colour tissue Doppler imaging. Data were stored on
compact discs and analyzed off-line with commercially
available software (EchoPAC software) by an experi-
enced investigator, with no other relation to the present
study and blinded to all other information.
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Simpson’s apical biplane method was used to evaluate
LV ejection fraction (LVEF) and left ventricular systolic
dysfunction was defined as LVEF < 50% [15,16]. Pulsed
wave Doppler examination of mitral inflow was per-
formed at the tip of the mitral leaflets in the apical long-
itudinal chamber view. Peak velocities of early (E [m/s])
and atrial (A [m/s]) diastolic filling, deceleration time of
the E wave (DT [ms]) and isovolumetric relaxation time
(IVRT [ms]) were measured [15]. We also used tissue
Doppler imaging of the LV basal annular longitudinal
myocardial shortening as defined by the annular peak
systolic velocity (s’ [cm/s]) and the two lengthening
velocities as defined by peak early mitral annular diasto-
lic velocity (e’lateral [cm/s]) and peak atrial mitral annu-
lar diastolic velocity (a’ [cm/s]), respectively. All tissue
Doppler measurements were performed at the lateral
border of the mitral annulus.
Normal LV diastolic function was defined as E/A ratio
0.7-1.5, DT 140-240 ms and e’lateral ≥ 10 [16,17].
Impaired LV relaxation (grade I diastolic dysfunction)
was detected when the E/A ratio was < 0.7, DT > 240 ms
and e’lateral < 10. A pseudonormal relaxation pattern
(grade II diastolic dysfunction) was diagnosed when the
E/A ratio was 0.7-1.5 ms, DT 140-240 ms and e’lateral <
10. Restrictive physiology (grade III diastolic dysfunction)
was deduced when E/A ratio was > 1.5, DT < 140 and
e’lateral < 10 [16,17]. Patients were required to display
the specific Doppler criteria described above in order to
be classified in a given category (grade) of LV diastolic
dysfunction. Patients with only 1 or 2 criteria present or
incomplete measurements were classified as having inde-
terminate diastolic dysfunction [18].
LV structure
We calculated LV mass = (0.8 [1.04 (LVIDd + PWTd +
SWTd)
3 -(LVIDd)
3]) +0.6 g [15,19]. LV mass was indexed
according to both body surface area (BSA = weight (kg)
0,425 × height (cm)
0,725 × 71,84 × 10
-4) and body height in
order to allow for comparison of data with other studies,
and, importantly, we indexed LV mass according to height
2.7 (LV mass/height
2.7) because the latter index has been
suggested to be optimal for indexing LV mass and grading
of LV hypertrophy in obese subjects [15,20]. Normal
values of LV mass and geometry according to recommen-
dations [15]. In particular, LV hypertrophy according to
LV mass/height
2.7 criteria was defined by LV mass index >
48 g/m
2.7 in men and > 44 g/m
2.7 in women, including
moderate-severe LV mass as defined by LV mass index >
55 g/m
2.7 in men and > 51 g/m
2.7 in women, respectively.
We also classified LV geometry in four mutually exclusive
groups on the basis of LV mass and relative wall thickness
(2 × PWTd)/LVDd) including 1) concentric hypertrophy
(increased LV mass > 115 g/m
2 in men and > 95 g/m
2 in
women and increased relative wall thickness > 0.42),
2) eccentric hypertrophy (increased LV mass and normal
relative wall thickness), 3) concentric remodeling (normal
LV mass and increased relative wall thickness), and 4) nor-
mal geometry (normal LV mass and normal relative wall
thickness) [15].
Left atrial (LA) volume was measured in apical 4 cham-
ber and 2 chamber views by the biplane area-length
method and was indexed to BSA. Right atrial (RA)
volume was measured in apical 4 chamber view by single
area-length method and indexed to BSA. Mild, moderate
and severe dilatation of LA or RA were defined as atrial
volumes of 29-33, 34-39 and > 39 ml/m
2, respectively, for
both women and men [15]. Moderate-severe increase of
LV diastolic volume was defined as LV diastolic volume/
BSA > 86 ml/m
2 for both women and men [21].
The study was approved by the local ethics committee
and all patients gave written informed consent.
Statistical analysis
Our primary objective was to describe if patients with
elevated NT-proBNP have more echocardiographic
abnormalities. Accordingly, we investigated if patients
with P-NT-proBNP levels above our previous defined
cut-off value (45.2 ng/l) had more echocardiographic
abnormalities than patients with P-NT-proBNP below
this value [10]. Furthermore, we examined the associa-
tions between echocardiographic measurements and CV
risk factors including P-NT-proBNP as a continuous
variable in univariate and multivariate linear regression
analyses. Finally, patients were divided into groups with
or without significant CAD and here we assumed that
the 67 low risk patients did not have significant CAD in
agreement with their low P-NT-proBNP and CCS, and
the comparatively good prognosis seen in these patients
[10]. The association of echocardiographic variables with
the presence of significant CAD were assessed by two
logistic regression enter models and expressed as
adjusted odds ratios (ORs) and 95% confidence intervals
(CIs). All included CV risk factors and echocardiographic
variables were selected according to significant associa-
tions observed in univariate analyses. The first logistic
regression model included conventional echocardio-
graphic data and the second model also included one tis-
sue Doppler variable (E/e’ lateral ratio). Due to co-
linearity of different measurements of mitral inflow and
t i s s u eD o p p l e rv a r i a b l e sw eo n l yu s e dE / Ar a t i oa n dE / e ’
lateral ratio in these analyses, respectively. Finally, these
analyses were also performed without inclusion of the
low risk patients that did not undergo MPI, CTA and
CAG examination. Data were expressed as means ± SD,
except for non-normally distributed variables, which
were log10-transformed before analysis and are given as
medians (interquartile range). All data were analyzed by
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14 for Windows. A p value less than 0.05 was considered
as statistically significant.
Results
Patient characteristics
The clinical characteristics of all patients and in patients
with P-NT-proBNP levels below and above our cut-off
value ( > 45.2 ng/l) are summarized in Table 1.
Of note, the multifactorial medical treatment for CV
disease prevention included statins (94% of patients),
aspirin (90%), and RAAS-blocking agents (98%).
Furthermore, 33%, 28%, and 17% received 2, 3, and ≥ 4
antihypertensive drugs on top of RAAS blockade.
Prevalences overall of echocardiography abnormalities
Echocardiography was completed in 99% (198/200) of
the patients. One patient died from liver cancer before
echocardiography and the data from another subject
was deleted by accident. Significant valvular disease was
seen in one patient with moderate aortic valve insuffi-
ciency, where LV size and systolic function were normal.
Echocardiographic measurements are shown in Table 2.
LV structure and function
LV mass, LV hypertrophy indexed to BSA/height and
height
2.7 and LV geometry are shown in Table 3. Moder-
ate-severe LV hypertrophy was more common when
indexed to ideal body size, e.g.: LV hypertrophy according
Table 1 The clinical characteristics of patients with plasma NT-proBNP below and above our defined cut-off value
All
patients
(n = 200)
Patients with NT-proBNP ≤ 45.2
ng/l (n = 96)
Patients with NT-proBNP > 45.2 ng/
l (n = 104)
p-
values
Sex no. (male%) 76 78 74 0.51
Age (years) 59 ± 9 55.4 ± 10 61.7 ± 9 0.0001
Known duration of diabetes (years) 13 ± 7 10.8 ± 7 14.6 ± 7 0.
0.001
BMI (kg/m
2) 32.6 ± 5.8 32.9 ± 5.6 32.3 ± 5.9 0.48
HbA1c (%) 7.9 ± 1.3 8.00 ± 1.3 7.7 ± 1.4 0.18
Systolic blood pressure (mmHg) 130 ± 17 131 ± 16 130 ± 18 0.55
Diastolic blood pressure (mmHg) 75 ± 11 76 ± 10 74 ± 12 0.18
Total cholesterol (mmol/l) 3.9 ± 0.9 4.1 ± 0.9 3.8 ± 1.0 0.032
Plasma creatinine (μmol/l) 76 ± 18 71.9 ± 16 80.6 ± 19 0.001
Haemoglobin (mmol/l) 8.6 ± 0.85 8.8 ± 0.9 8.4 ± 0.9 0.001
Heart rate variability during deep breathing
(bpm) *
7 (4.5-11.5) 8 (42-205) 6 (4-10) 0.0001
Vibratory perception threshold mV - mean of
both sides
33 ± 15 28.5 ± 14 37.9 ± 14 0.0001
Retinopathy no. (%) 120 (60) 44 (45) 76 (73) 0.0001
Urinary albumin excretion rate (mg/24 h)* 103 (39 -
230)
103 (38 - 491) 101 (38 - 286) 0.70
Peripheral systolic blood pressure (mmHg -
worst big toe)
121 ± 34 125 ± 32 117 ± 35 0.35
Carotid intima-media thickness (mm) 0.73 (0.15) 0.71 ± 0.16 0.75 ± 0.14 0.15
Carotid compliance
a (l/mmHg) 0.0026 ±
0.001
0.0025 ± 0.001 0.0026 ± 0.001 0.30
Coronary Calcium Score* 183 (0-
4529)
87 (1-426) 251 (24-872) 0.014
Oral antidiabetic medication no. (%) 170 (85) 85 (89) 85 (82) 0.18
Insulin treatment no. (%) 124 (62) 59(61) 65 (63) 0.88
RAAS blockade no. (%) 196 (98) 94 (98) 102 (98) 0.94
Statin therapy no. (%) 189 (95) 91 (95) 98 (94) 0.82
Aspirin therapy no. (%) 183 (92) 87 (91) 96 (92) 0.80
Beta-blocker therapy no. (%) 27 (14) 4 (4) 23 (22) 0.0001
Calcium channel blockers no. (%) 80 (40) 36 (36) 44 (44) 0.25
Diuretics no. (%) 128 (64) 56 (58) 72 (69) 0.11
Our plasma NT-proBNP cut-off value has previously been defined but represented the median NT-proBNP in the first 50 patients examined in the study [10].
p-values reflect comparison between patients with high and low plasma NT-proBNP levels
Data are expressed as means (SD) or medians, interquartile range*
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2.7 criteria was present in 24% (48/200)
of patients, including 9% (18/200) of patients with moder-
ate-severe LV hypertrophy. Whereas LV hypertrophy
according to LV mass/BSA criteria was only seen in 10%
of patients, including 4% (7/200) of patients with moder-
ate-severe LV hypertrophy. In addition, normal LV geo-
metry was present in 36% of patients and the distribution
of concentric hypertrophy, eccentric hypertrophy and con-
centric remodelling were 10%, 1% and 52% of patients,
respectively. Only 3% (5/200) had moderate-severe
enlarged diastolic LV volume (not shown).
Five% (10/200) of patients had LV systolic dysfunction.
In contrast, LV diastolic dysfunction was detected in 55%
(109/200) patients while 37 had normal diastolic
echocardiographic findings and 54 were categorized as
displaying indeterminate diastolic dysfunction according
to presence of only 1 or 2 tissue Doppler criteria for LV
diastolic dysfunction (n = 42) or because of incomplete
diastolic measurements (n = 12). Among the 109 patients
who had LV diastolic dysfunction, impaired LV relaxa-
tion (grade I diastolic dysfunction) was detected in 4%
(7/200) and a pseudonormal LV relaxation pattern (grade
II) was detected in 51% (102/200) of subjects. Restrictive
physiology (grade III) was not noted in any patient.
Finally, LV E/e’ratio was increased ( > 10) in 24% (48/
200) of patients, and these patients did not have
increased LA volumes compared to patients with normal
E/e’ratio. Associations between CV risk factors and
Table 2 The echocardiographic measures of patients with plasma NT-proBNP below and above our defined cut-off
value
All patients
(n = 200)
Patients with NT-proBNP ≤
45.2 ng/l (n = 96)
Patients with NT-proBNP >
45.2 ng/l (n = 104)
p-values
Left ventricular structure
Left ventricular end-diastolic volume [ml] 127.0 ± 28.9 129 ± 28.5 130 ± 31.9 0.85
Left ventricular end-systolic volume [ml] 52.0 ± 15.5 53.5 ± 16.7 53.9 ± 16.7 0.74
Left atrial volume index biplane [ml/m
2] 25.6 ± 6.4 24.5 ± 6.1 26.7 ± .6.7 0.021
LV mass, g, 188.8 ± 52.6 203.1 ± 48.0 180.9 ± 53.5 0.11
LV mass/height
2,7, [g/m
2.7] 41.2 ± 10.9 39.85 ± 10.8 42.43 ± 10.7 0.10
Left ventricular systolic function
Left ventricular ejection fraction [%] 59.5 ± 4.8 58.6 ± 5.7 59.9 ± 4.3 0.50
Peak mitral annular systolic velocity (s’) [cm/s] 8.49 ± 1.58 8.71 ± 1.60 8.28 ± 1.54 0.057
Left ventricular diastolic function and grade
Isovolumetric relaxation time [ms] 86.1 ± 15.8 88.3 ± 17.6 84.8 ± 14.7 0.14
Mitral valve E-wave deceleration time [ms] 201.0 ± 39.5 203.8 ± 38.0 199.6 ± 40.4 0.48
Mitral valve E-wave deceleration slope [m/s2] 3.7 ± 1.1 3.7 ± 1.1 3.8 ± 1.1 0.088
Peak mitral valve E-velocity [m/s] 0.71 ± 0.15 0.71 ± 0.15 0.71 ± 0.15 0.95
Peak mitral valve A-velocity [m/s] 0.93 ± 0.22 0.82 ± 0.17 0.77 ± 0.17 0.033
E/A ratio 0.93 ± 0.20 0.94 ± 20 0.92 ± 0.23 0.60
Peak early mitral annular diastolic velocity (e’ lateral)
[cm/s]
8.86 ± 2.34 9.23 ± 2.55 8.50 ± 2.06 0.032
Peak atrial mitral annular diastolic velocity (a’) [cm/s] 9.82 ± 2.28 10.21 ± 2.18 9.62 ± 2.31 0.088
E/e’ lateral ratio 8.51 ± 2.63 9.10 ± 2.89 7.94 ± 2.71 0.025
Diastolic dysfunction grade I no. (%) 7 (3.5) 2 (2) 6 (6) 0.12
Diastolic dysfunction grade II no. (%) 102 (51) 47 (49) 55 (53) 0.31
Diastolic dysfunction grade III no. (%) 0 0 0 -
Right ventricular structure and function
Right atrial volume single plane [ml/m
2] 23.7 ± 9.0 22.4 ± 8.7 25.2 ± 9.2 0.033
Mid-RV diameter [cm] 3.9 ± 0.5 4.0 ± 0.5 3.9 ± 0.5 0.34
Tricuspid annular plane systolic excursion ^[cm] 2.65 ± 0.45 2.62 ± 0.43 2.67 ± 0.45 0.47
Peak tricuspid regurgitation gradient ~ [mmHg] 18.2 ± 7.2 17.4 ± 6.8 18.5 ± 7.3 0.44
Our plasma NT-proBNP cut-off value has previously been defined but represented the median P-NT-proBNP in the first 50 patients examined in the study [10].
p-values reflect comparison between patients with high and low plasma NT-proBNP
Data are expressed as means ± SD or medians, interquartile range*
Left ventricular (LV)
Right ventricular (RV)
^no patients had tricuspid annular plane systolic excursion less than 1.5 cm
~ 65 of all patients had no tricuspid regurgitation, 111 had discrete and 5 patients had mild tricuspid regurgitation. In 19 patients we were not able to evaluate
tricuspid regurgitation.
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not significant after adjustment for age and sex (not
shown). However, we demonstrated a strong independent
correlation between LV diastolic dysfunction and poor
glycaemic control (the adjusted OR of having LV diasto-
lic dysfunction was 2.42 (1.36-4.31) per 1% increase of
HbA1c after adjustments for age, sex and all described
CV risk factors, p = 0.003).
Atrial size
LA volume was abnormal in 27% of (54/200) patients, with
moderate-severe LA dilatation in 7% (14/200) of patients,
where as RA volume was abnormal in 23% (45/200) of
patients, including 9% (18/200) of subjects with moderate-
severe RA dilatation.
Plasma NT-proBNP levels and echocardiographic
abnormalities
Echocardiographic variables in patients with P-NT-proBNP
levels below and above cut-off value are described in Table
1. Subjects with elevated P-NT-proBNP levels did not have
more LV hypertrophy, manifest atrial dilatation and LV
dysfunction than patients with NT-proBNP levels below
this value (p > 0.05). We did, however demonstrate that
patients with P-NT-proBNP levels above cut-off value had
higher LA volume index within the normal limits (26.7 ±
6.7 vs. 24.5 ± 5.8 ml/m
2,p=0 . 0 2 1 ) ,h i g h e rR Av o l u m e
index (25.2 ± 9.2 vs. 22.4 ± 8.7 ml/m
2, p = 0.033) and
increased E/e’ratio (9.10 ± 2.89 vs. 7.94 ± 2.71, p = 0.003)
than patients with NT-proBNP levels below this value. LA
or RA volume index remained significantly different after
adjustment for age, sex and CV risk factors shown in Table
2 but not when significant CAD was introduced (p > 0.05).
We also demonstrated a borderline lower peak systolic per-
formance (8.28 ± 1.54 vs. 8.71 ± 1.60 cm/s, p = 0.057) in
patients with P-NT-proBNP levels above our cut-off value.
LV mass indexed to height
2.7 was not significantly different
among the two groups (p > 0.05).
Associations between echocardiographic variables and
significant CAD
In total, 70 high risk patients had significant CAD
defined by abnormal MPI and/or CAG, representing
35% (70/200) the population.
The capabilities of selected echocardiographic variables
to predict significant CAD were assessed in the two logis-
tic regressions models and expressed as adjusted ORs. In
both models elevated LV mass/height
2.7 even within nor-
mal values was the only independent predictor of signifi-
cant CAD, (adjusted ORs were 1.88 [1.12-3.15] and 2.50
[1.19-5.23] per 10 g increase for model 1 and 2, respec-
tively). Importantly, the strong independent association
between LV mass/height
2.7 and significant CAD was also
seen in both models without inclusion of the low risk
patients (p = 0.015). Finally, patients with LV hypertro-
phy (as defined by LV mass/height
2.7) had an OR of 4.53
(1.14-18.06) for significant CAD (model 1).
Discussion
Principal findings
We determined the prevalence of echocardiographic
abnormalities, including LV hypertrophy, RA and/or LA
dilatation, and LV systolic and diastolic dysfunction,
respectively, and their relation to P-NT-proBNP levels or
significant CAD in asymptomatic type 2 diabetic patients
with microalbuminuria that received intensive multifac-
torial treatment. In these patients, P-NT-proBNP levels
were not associated with echocardiograpic abnormalities.
LV hypertrophy was present in 24% when indexed to
height
2.7 and LV diastolic dysfunction was observed in
Table 3 Left ventricular mass, hypertrophy as defined by indexing of body surface area, regular height and height
2.7,
and geometry in 200 type 2 diabetic patients with elevated urinary albumin excretion rate
Left ventricular (LV) hypertrophy in women (n = 46)* Normal no. (%) Mild no. (%) Moderate no. (%) Severe no. (%)
LV mass, g, 67-162, 163-186, 187-210 and ≥ 211 24 (52) 10 (22) 7 (15) 5 (11)
LV mass/BSA, g/m
2, 43-95, 96-108, 109-121 and ≥ 122 40 (87) 3(7) 1(2) 2 (4)
LV mass/height, g/m, 41-99, 100-115, 116-128 and ≥ 129 24 (52) 14 (30) 5 (11) 3 (7)
LV mass/height
2,7, g/m
2,7, 18-44, 45-51, 52-58 and ≥ 59 28 (61) 14 (30) 2 (4) 2 (4)
Relative wall thickness, cm, 0.22-0.42, 0.43-0.47, 0.48-0.52 and ≥ 0.53 19 (41) 8 (17) 9 (20) 10 (22)
LV hypertrophy in men (n = 149)* Normal no. (%) Mild no. (%) Moderate no. (%) Severe no. (%)
LV mass, g, 88-224, 225-258, 259-292 and ≥ 293 111 (75) 21 (14) 8 (5) 9 (6)
LV mass/BSA, g/m
2 49-115, 116-131, 132-148 and ≥ 149 135 (91) 10 (7) 2 (1) 2 (1)
LV mass/height, g/m, 52-126, 127-144, 145-162 and ≥ 163 116 (78) 17 (11) 11 (7) 5 (3)
LV mass/height
2,7, g/m
2,7, 20-48, 49-55, 56-63 and ≥ 64 119 (80) 16 (11) 10 (7) 4 (3)
Relative wall thickness, cm, 0.24-0.42, 0.43-0.46, 0.47-0.51 and ≥ 0.52 56 (38) 27 (18) 29 (19) 37 (25)
LV mass was calculated using the formula = 0.8 1.04[(LVIDd + PWTd + SWTd)3 - (LVIDd)3] + 0.6 g and indexed to body surface area (BSA), regular height and
height
2.7. LV relative wall thickness; 2 × PWd/LVDd. Reference limits are shown in the table.
* of the 200 patients, we did not perform echocardiography in two men and in addition it was no possible to measure left ventricular mass in two women and
one man due to poor echocardiographic windows
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2.7 and
LV hypertrophy but not LV diastolic dysfunction were
strongly and independently associated with significant
CAD.
Plasma NT-proBNP and echocardiographic abnormalities
We have previously demonstrated a strong and indepen-
dent risk for CV mortality with elevated P-NT-proBNP
in type 2 diabetic patients [3], and in the present study
we therefore investigated if echocardiographic abnormal-
ities, that holds important prognostic value, were more
common in patients with increased P-NT-proBNP levels
[5]. Our subjects with increased P-NT-proBNP levels did
not have more LV hypertrophy, manifest atrial dilatation
and LV systolic or diastolic dysfunction but we demon-
strated that left and right atrial volume indexes within
the normal limits were independently higher in patients
with increased NT-proBNP. In animal models, BNP gene
expression reflect atrial and ventricular pressures [22] In
elderly human subjects LA > 32 ml/m
2 was associated
with an increased risk of heart failure [23]. However, this
cut-off represents 2 SDs from the normal mean LA
volume of 22 ± 5 ml/m
2 and it is therefore difficult to
translate our of finding of 2.2 ml/m
2 difference between
the two groups. In contrast, the LA dilates in response to
the chronic increased LV and LA filling pressures and
therefore as such is a sensitive cumulative marker of dia-
stolic dysfunction. Accordingly, a small structural change
of LA volume could therefore reflect long-term risk (NT-
proBNP) rather than the functional diastolic echocardio-
graphic parameters, which are more subject to high fluc-
tuation with preload and other short term conditions.
This could also explain why NT-proBNP was not related
to diastolic dysfunction as described in the present study.
This is in line with some studies [24], however other stu-
dies have shown that BNP is an early determinant of
both diastolic and systolic dysfunction. Specifically, in
asymptomatic newly diagnosed diabetic patients, it has
been demonstrated that BNP is associated with the pre-
sence of diastolic dysfunction [4]. Accordingly, the use of
BNP in the screening for preclinical moderate-severe dia-
stolic dysfunction in diabetic patients has been suggested
[25]. Finally, BNP is increased in subjects with systolic
dysfunction in the general population [26]. The prognos-
tic value of right atrial volume index is even more scar-
cely described but the right atrial association with
NT-proBNP has previously been reported in other sub-
jects [27]. The association in the latter study, was particu-
lar important when pulmonary hypertension occurred as
a result of chronic obstructive pulmonary disease [27].
Therefore a pulmonal component of poor prognosis
might be revealed in this study, however the true mean-
i n go fN T - p r o B N P ,l e f ta n dr i g h ta t r i a lv o l u m e sw i l lb e
examined in our planned follow-up of these patients.
Other limitations may explain why patients with
increased NT-proBNP levels did not have more major
echocardiographic abnormalities in the present study.
First, patients in the present study were without prior
heart disease and all patients had normal P-creatinine
where as subjects in our earlier study with higher preva-
lence of echocardiographic abnormalities included all
type 2 diabetic patients followed in an out-patient clinic
(4). Second, the increasingly intensive treatment used
today in our patients is likely to have influenced the
results compared to the earlier study [28], since almost
all of our patients received statins, aspirin, and RAAS
blockade. Noteworthy, in the Steno-2 study, the P-NT-
proBNP levels increased over time in all patients, but was
less in the intensive therapy group [28]. Furthermore, as
shown in Table 2, some modifiable risk factors targeted
by the multifactorial treatment were lower in patients
with high NT-proBNP (cholesterol, bloodpressure but
not haemoglobinA1c), where as the non-modifiable risk
factors such as diabetes duration, plasma creatinine and
signs of peripheral artery disease were higher in patients
with high NT-proBNP. Along this line and as discussed
below, the low prevalences of echocardiographic moder-
ate-severe abnormalities in this study might also dilute
the putative associations with NT-proBNP levels. Third,
other factors such as cardiac autonomic neuropathy, is
likely to influence CV mortality. Of note, we have pre-
viously reported the correlations between NT-proBNP
and significant CAD and/or atherosclerosis in different
territories. Along this line, NT-proBNP levels might be
a more sensitive marker of early asymptomatic prognos-
tic ventricular disease than the echocardiographic
examination.
Echocardiographic abnormalities and intensive
multifactorial treatment
Individual and multifactorial intensive interventions
including polypharmacologic therapy according to the
Steno-2 study is the current standard of care in our
institution and is known to reduce CV morbidity and
mortality [1]. Noteworthy, an audit compared the levels
of treatment targets before and after the Steno-2 study
(2002 and 2009) and demonstrated that the Steno-2
study results of lowering haemoglobinA1c, lipids and
blood pressure were successfully implemented into clini-
cal practise at Steno Diabetes Center [29]. Almost all
patients in the current study received statins, aspirin
and RAAS blockading agents, and 33%, 28%, and 17%
received 2, 3, and ≥ 4 antihypertensive drugs on top of
RAAS blockade. Indeed, this intensive treatment yielded
mean total cholesterol levels of 3.9 mM, arterial blood
pressures of 130/75 mmHg, and haemoglobinA1c levels
of 7.9%, respectively, which may explain why most of
the conventional CV risk factors as well as levels of
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variables in our study (Table 2).
The reported prevalence of LV hypertrophy depends
on classification criteria and population characteristics,
ranging from 3% in the normotensive general population
to almost 75% in hypertensive patients. The LV hyper-
trophy diagnosis varies with the methods, formulas,
indexing and cut-off values that are applied. In a recent
relatively large echocardiographic study with use of
equivalent methods and classification schemes as used
in our current study, moderate-severe LV hypertrophy
(g/m
2) was present in 13% of 305 type 2 diabetic
patients [16]. That study included asymptomatic patients
referred to a diabetes clinic for the first time with less
than 5 years of diabetes duration and without prior CV
disease. In comparison, moderate-severe LV hypertrophy
(g/m
2) was only seen in 4% of our cases despite that our
patients had microalbuminuria and frequently demon-
strated other signs of microvascular disease (retinopathy
and neuropathy) with average diabetes duration of 13
years. In a previous study with use of different echocar-
diographic methods and cut-off values, we reported that
LV hypertrophy (g/m
2) was present in 75% or 51% of
type 2 diabetic patients with or without diabetic nephro-
pathy, respectively, and in 9% of controls [30]. In
another study that included 426 normoalbuminuric type
2 diabetic patients without cardiovascular disease and
not taking antihypertensive treatment, we also showed
that LV hypertrophy (g/m
2.7) was present in 43% of sub-
jects [7]. Had these previously used criteria been used in
the present study we would have demonstrated LV
hypertrophy in 21% (g/m
2) or 46% (g/m
2.7)o fp a t i e n t s ,
respectively (data not shown). The similar prevalence of
LV hypertrophy in patients with normoalbuminuria as
observed in our previous study (5) and the higher preva-
lence of LV hypertrophy in newly referred diabetic
patients [16], compared to our complicated patients
with microalbuminuria suggests that the prevalence of
LV hypertrophy has been reduced by multifactorial
treatment. This is in line with our recent finding that
the prevalence of carotid intima-media thickness was
indeed lower than expected in the present cohort [8].
The beneficial effect of antihypertensive agents on LV
hypertrophy in diabetics is well-established, although the
regression of LV hypertrophy in these patients appears
to be less than in subjects without diabetes [31]. LV
hypertrophy and even increased LV mass within normal
values were associated with significant CAD, and this
observation may contribute to the previously described
higher CV mortality in diabetic patients with residual
LV hypertrophy despite treatment [9,32]. Whether addi-
tional treatment aimed at reduction of LV hypertrophy
in diabetes patients on intensive multifactorial treatment
(with or without CAD) can ameliorate prognosis
remains to be determined.
Our finding of more than 50% of patients with LV
diastolic dysfunction in the present cohort was not
unexpected, since LV diastolic dysfunction is considered
to be resistant to medical treatment and prevalent in
diabetic patients [5,16]. The pathogenesis of LV diastolic
function is not known in detail, but a contribution of
increased afterload, e.g. due to augmented arterial stiff-
ness and microvascular disease, reduced myocardial per-
fusion, and increased myocardial stiffness associated
with extracellular matrix alterations, fibrosis and meta-
bolic derangements have been suggested [33]. Interest-
ingly, LV diastolic dysfunction was not related to LV
mass or carotid compliance in patients with or without
significant CAD, but a strong association with glycaemic
control (HbA1c levels) was found. This finding is in
accordance with the hypothesis that hyperglycaemia can
induce increased myocardial stiffness, e.g. by extracellu-
lar advanced glycation products leading to myocardial
fibrosis [33]. No patients had restrictive LV diastolic
dysfunction and only 4 patients had E/e’ >1 5w h i c h
would indicate severely increased LV filling pressures
and is considered to be pathognomonic for diastolic
heart failure in the presence of heart failure symptoms
and normal LV systolic function [27]. The prevalence of
moderate-severe LA dilatation was also low and particu-
lar severely abnormal LA volume ( ≥ 40 ml/m
2)w a s
only observed in 5 patients. A recent study reported LA
distension ( > 32 ml/m
2) in almost one third of patients
with a lower CV risk profile compared to our study
cohort [16]. These observations add to the notion that
intensive multifactorial treatment may reduce the detri-
mental cardiac consequences of diabetes and hereby
potentially delay clinical heart failure and reduce CV
mortality. However, as stated above the true clinical
impact of the presence of echocardiographic abnormal-
ities in our present cohort of aggressively treated
patients will be examined by planned prospective fol-
low-up.
Conclusion
Among asymptomatic type 2 diabetic patients with
microalbuminuria that received intensive multifactorial
treatment, patients with increased P-NT-proBNP levels
did not have more echocardiographic abnormalities. LV
diastolic dysfunction was frequently observed, where as
LV hypertrophy was less frequ e n ta n da s s o c i a t e dw i t h
significant CAD.
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